SCHEDULE 13G/A: Longitude Capital Reduces Stake in Lexeo Therapeutics

Longitude Capital Partners IV, LLC and related entities have updated their beneficial ownership in Lexeo Therapeutics, Inc. to 3.8% of common stock.

Summary

• Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Patrick G. Enright, and Juliet Tammenoms Bakker (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
• The Reporting Persons beneficially own 2,765,381 shares of Lexeo Therapeutics, Inc. common stock.
• This represents 3.8% of the total 72,987,327 shares outstanding as of November 3, 2025.
• All shares are held of record by Longitude Venture Partners IV, L.P.
• Longitude Capital Partners IV, LLC is the general partner of Longitude Venture Partners IV, L.P., and Patrick G. Enright and Juliet Tammenoms Bakker are managing members of Longitude Capital Partners IV, LLC, all sharing voting and dispositive power over these securities.
• The filing indicates ownership of 5 percent or less of the class, implying a reduction from a previously higher reported stake.

Sentiment

Score: 4

Explanation: The filing reports a beneficial ownership of 3.8%, which is below the 5% threshold typically associated with significant institutional stakes. As an Amendment No. 2, this implies a reduction from a previously higher reported ownership, which could be interpreted as a negative signal regarding the investor's conviction in Lexeo Therapeutics.

Positives

• The continued disclosure by Longitude Capital, a venture capital firm, indicates ongoing interest in Lexeo Therapeutics, Inc.
• The stake, while below 5%, is still substantial, suggesting a degree of confidence in the company's long-term prospects from a sophisticated investor.

Negatives

• The reduction in beneficial ownership to below 5% (implied by the "Ownership of 5 Percent or Less" statement and the 3.8% figure) could be interpreted as a decrease in conviction or a strategic divestment by Longitude Capital.

Risks

• A decrease in a significant institutional investor's stake could signal potential concerns about the company's future performance or valuation, which might influence other investors.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an institutional investor's stake. In the biotechnology or pharmaceutical industry, institutional ownership changes are closely watched as they can reflect investor sentiment regarding drug development pipelines, clinical trial results, or regulatory approvals. A reduction in stake by a venture capital firm like Longitude Capital could be a normal part of their investment lifecycle (e.g., taking profits) or a response to specific company or industry developments.

Stakeholder Impact

• Shareholders may interpret the reduction in Longitude Capital's stake as a negative signal, potentially leading to downward pressure on the stock price.
• Management might face questions regarding the reasons for the reduction in institutional ownership.

Key Dates

Recommendation

While the implied reduction in Longitude Capital's stake to 3.8% is a notable event, a Schedule 13G filing alone does not provide sufficient operational or financial data to make a definitive buy or sell recommendation. It primarily reflects an investor's position. A "Hold" recommendation is appropriate as further analysis of Lexeo Therapeutics' fundamentals, pipeline, and market conditions would be required to assess the long-term implications of this ownership change.

Keywords

Lexeo Therapeutics, Longitude Capital, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake, 52886X107